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Abstract
Laminins, a large family of abc heterotrimeric proteins mainly found in basement membranes, are strong promoters of
adhesion and migration of multiple cell types, such as tumor and immune cells, via several integrin receptors. Among
laminin a (LMa) chains, a5 displays the widest tissue distribution in adult life and is synthesized by most cell types. Here, we
have generated and characterized five novel monoclonal antibodies (mAbs) to the human LMa5 chain to further study the
biological relevance of a5 laminins, such as laminins 511 (a5b1c1) and 521 (a5b2c1). As detected by ELISA,
immunohistochemistry, immunoprecipitation and Western blotting, each antibody displayed unique properties when
compared to mAb 4C7, the prototype LMa5 antibody. Of greatest interest, mAb 8G9, but not any other antibody, strongly
inhibited a3b1/a6b1 integrin-mediated adhesion and migration of glioma, melanoma, and carcinoma cells on laminin-511
and, together with mAb 4C7, on laminin-521. Accordingly, mAb 8G9 abolished the interaction of soluble a3b1 integrin with
immobilized laminins 511 and 521. Binding of mAb 8G9 to laminin-511 was unaffected by the other mAbs to the LMa5
chain but largely hindered by mAb 4E10 to a LMb1 chain epitope near the globular domain of laminin-511. Thus, mAb 8G9
defines a novel epitope localized at or near the integrin-binding globular domain of the LMa5 chain, which is essential for
cell adhesion and migration, and identifies a potential therapeutic target in malignant and inflammatory diseases.
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Laminins are a family of large adhesive heterotrimeric
molecules composed by disulfide-bonded a, b, and c chains
[1,2,3,4]. These proteins are major components of basement
membranes (BMs) and effectors of tissue architecture, but can also
be found in other anatomical locations [1,2,3,4]. To date, five a,
three b, and three c laminin chains have been reported in the
literature, which assemble into more than 15 laminin isoforms
[1,2,3,4]. In the recent nomenclature, laminins are named
according to their chain composition [2]. Thus, laminin a4b2c1,
previously called laminin-9, is now denominated laminin-421.
Laminins are synthesized by numerous cell types of solid tissues,
and expression of the various laminin isoforms, particularly their a
chain, is cell and tissue specific [3,4,5]. The prototype laminin-
111, originally isolated from a mouse tumor in 1979 [6], has been
well characterized biochemically, and much of the in vitro
functional data ascribed to laminins are based on studies
performed with this laminin isoform [1,3,4]. However, expression
of the laminin a1 (LMa1) chain in adult tissues is highly restricted
to a limited subpopulation of epithelial cells [7,8]. In contrast, the
other and more recently described laminin a chains (LMa2-a5),
which constitute most laminin isoforms, have a much wider tissue
distribution but their actions on cells are less well understood or
unknown [3,4]. The physiological relevance of laminin a chains is
illustrated by congenital muscular dystrophy and junctional
epidermolysis bullosa, two genetic human diseases of muscle and
skin caused by mutations in LMa2 and a3 chains, respectively
[1,3,4]. Laminins are recognized, through their a chain, by nearly
ten different integrins in an isoform –specific fashion and strongly
promote cell adhesion and migration [3,4,5]. a3b1, a6b1, a7b1
and a6b4 are known as ‘‘classical’’ laminin-binding integrins [9].
LMa5 is the largest of all laminin chains (nearly 3700 amino
acids, 350 kDa) and the most widely expressed laminin a chain in
adult life [1,10,11,12]. Nevertheless, it was the last laminin a chain
to be identified. It constitutes laminin-511 (laminin 10), laminin-
521 (laminin 11) and laminin-523 (laminin 15), and is present in
epithelial BM (laminin-511) and vascular endothelial BM (laminin-
511 and laminin-521), as well as in lymph nodes, lung, kidney and
many other organs [1,2,3,4,13]. Most normal and malignant cells
can synthesize and secrete a5-laminins [1,3,14–24]. Deletion of
the LMa5 gene is lethal as deficient mice die during fetal life
because of multiple malformations [25]. Among human laminin a
chains, LMa5 is unique in containing functional RGD sequences
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[12,26]. An RGD sequence found in the short arm of the mouse
LMa1 chain is not conserved in human LMa1 [26]. Recent
availability of both natural and recombinant laminin-511 has
demonstrated that a5-laminins strongly mediate adhesion and
migration of a large variety of cell types, including tumor and
immune cells, and binding assays have shown direct interaction of
isolated a3b1, a6b1, a7b1, a6b4 and aVb3 integrins with purified
laminin-511 [12,14,16,18,20,21,22,23,24,27,28,29,30,31,32]. Al-
though a3b1 and a6b1, and probably a7b1 and a6b4, integrins
recognize the laminin globular (LG) modules of the LMa5 chain
[33], aVb3 has been reported to bind the RGD-containing IVa
module of the short arm of this chain [26]. Lutheran blood group/
basal cell adhesion molecule (Lu/BCAM) (CD239), a member of
the immunoglobulin superfamily expressed by erythrocytes and
some epithelial cells, is another cell surface receptor for laminin-
511 and also binds the LG domain of the LMa5 chain
[33,34,35,36].
Antibodies are most valuable reagents for analyzing laminins
and other proteins. Since the end of the 1970s rabbit polyclonal
antibodies to mouse laminin-111 have been extensively used, but
these antisera cross-react with most laminin isoforms [1,3,4]. In
contrast, monoclonal antibodies (mAbs) are mostly laminin-chain
specific and can discriminate among laminin isoforms. In spite of
this, only a few mAbs against laminin a chains are currently
available. In previous studies we generated and characterized
several mAbs to the human LMa4 chain [30,37]. These reagents
have been most useful in the analysis of a4 laminins
[22,23,24,30,37].
Immunological reagents to the LMa5 chain are even scantier, in
spite of the obvious relevance of a5 laminins in cell and cancer
biology. mAb 4C7 is today the prototype antibody to LMa5 [38].
However, this antibody, which was generated by immunization
with ‘‘laminin’’ isolated from human placenta, was considered for
over a decade to be LMa1 specific, generating confusion in the
scientific literature [38,39]. The mAb 4C7 binds to LG1 of the
LMa5 chain and appears to interfere with some functions of a5
laminins, including a6b1 integrin binding, but its ability to inhibit
cell adhesion and migration seems to be limited [34,38,40,41]
Figure 1. Reactivity of novel mAbs to LMa5 chain as measured by ELISA, Western blotting and immunoprecipitation. A) Reactivity of
the antibodies with rhLMs 411, 511 and 521 by ELISA. B) Reactivity of the antibodies with rhLM511 by Western blotting under reducing conditions. C)
Ability of the antibodies to immunoprecipitate laminin-511 from A549 cells’ conditioned medium and detection of the LMa5 chain by Western
blotting with mAb 4B5. Bands of 300/350 kDa corresponding to LMa5 chain were detected with some of the antibodies.
doi:10.1371/journal.pone.0053648.g001
A Function-Blocking mAb to Laminin alpha5 Chain
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(present study). This antibody is excellent for immunohistochem-
istry of frozen sections, but its reactivity is reduced in formalin-
fixed and paraffin-embedded sections. Furthermore, it works
efficiently for immunoprecipitation, but not at all for Western
blotting [38,39] (present study).
In the present study, we report generation and characterization of
five novel mAbs to the LMa5 chain. As measured by ELISA,
immunohistochemistry, Western blotting and immunoprecipitation,
each antibody displays unique properties when compared to mAb
4C7. The mAb 4B5 efficiently reacted in Western blotting and, of
greater interest, mAb 8G9 strongly inhibited adhesion andmigration of
cancer cells on a5 laminins mediated by a3b1 and a6b1 integrins.
Materials and Methods
Production of novel mAbs to human LMa5 chain
Female Balb/c mice were first immunized with natural human
laminin-511 purified from A549 lung adenocarcinoma cells, as
described [14], using Freund’s complete adjuvant (Sigma-Aldrich;
St. Louis, MO, USA). Three further immunizations were made
using Freund’s incomplete adjuvant (Sigma-Aldrich) with the same
laminin. The last immunization was performed three days before
hybridization. Hybridomas were generated according to standard
methods [42]. In preliminary screening, hybridomas were tested
for reactivity with laminin-511 from A549 cells and placenta
laminin-211 (merosin) (Millipore, Billerica, MA, USA) by ELISA.
All selected antibodies were mouse immunoglobulin (Ig) G1. In the
final screening and in all other assays, recombinant human (rh)
laminins 411, 511 and 521 purchased from BioLamina (Stock-
holm, Sweden) were used. All animal work was conducted
according to relevant national and international guidelines, with
approval of the Institutional Animal Care and Use Committee of
Tartu University and the Estonian Department of Agriculture.
Mice were housed in the animal facility, provided standard rodent
chow and water ad libitum, and sacrificed with carbon dioxide.
Cell lines
In the present study, the following human cancer cell lines were used:
A549 lung adenocarcinoma [14,43], KG1C glioma [22], BEmelanoma
[24] and MDA-MB-231 breast carcinoma [44]. Cells were grown and
maintained in RPMI-1640 medium with 10% fetal bovine serum and
supplemented with HEPES buffer, penicillin and L-glutamine.
Enzyme-linked immunosorbent assay (ELISA)
For conventional ELISA, 96-well plates (Maxisorp, Nunc, Roskilde,
Denmark) were coated for 1 hour at room temperature (RT) with rh
laminins 411, 511 and 521 at 2 mg/ml. Following blocking with 0.5%
bovine serum albumin (BSA), mAbs were added at a final
concentration of 1 mg/ml and allowed to interact for 1 hour at 4uC.
After three washes with phosphate buffered saline (PBS), bound
antibodies were detected using goat antibodies to mouse Ig coupled to
horseradish peroxidase (HRP) (Dako, Glostrup, Denmark) and the
enzyme activity was measured using orthophenylenediamine (Sigma-
Aldrich). The plates were analyzed using a generic ELISA reader (at
492 nm). In addition to the novel antibodies, mAbs 4C7 (LMa5) [38],
3H2 (LMa4) [30], DG10 (LMb1) [45] and 22 (LMc1) (BD
Biosciences, Erembodegem, Belgium) [45] were used.
Immunoprecipitation and sodium dodecyl sulphate
(SDS)-polyacrylamide gel electrophoresis (PAGE)/Western
blotting
For immunoprecipitation, the primary antibody-antigen com-
plex was produced by mixing 20 ml of mAbs against LMa5 chain
Figure 2. Immunohistochemical reactivity of mAb 8G9 in comparison to mAb 4C7 against LMa5 chain. (A) and (C), mAb 4C7; (B) and (D),
mAb 8G9 against frozen sections of human kidney (A) and (B), and skin (C) and (D). The staining pattern of the two antibodies was indistinguishable.
In kidney, the antibodies stained glomerular and tubular basement membranes, whereas in skin, reactivity with epidermal and vascular basement
membranes was observed.
doi:10.1371/journal.pone.0053648.g002
A Function-Blocking mAb to Laminin alpha5 Chain
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(400 mg/ml) with 1 ml of conditioned medium from A549 cells. In
parallel, rabbit anti-mouse IgG was added to Protein G Sepharose
beads (GE HealthCare Biosciences, Uppsala, Sweden). Both
complexes were incubated separately under continuous inversion
for 1,5 hour at 4uC. Subsequently, the two complexes were mixed
and further incubated for 1,5–2 hours at 4uC. Unbound
complexes were washed away, and precipitated proteins were
dissociated by heating (100uC) for 5 minutes in SDS sample buffer
with mercaptoethanol. The protein sample was separated by SDS-
PAGE in a 5% polyacrylamide gel and electroblotted to a PDVF
membrane. The blots were incubated with specific primary mAbs
against LMa5 chain and detected with the HRP-conjugated
secondary Ab (Dako). A generic ECL reagent kit (GE Healthcare
Biosciences) was used for film development.
Immunohistochemistry
Specimens of normal human kidney and skin were obtained
from surgical operations and retrieved from the files of the
Institute of Biomedicine/Anatomy of the University of Helsinki
with institutional permission and approval from the Ethics
Committee of the Hospital District of Helsinki and Uusimaa
(#319/E0/2006). The material was derived from nonessential
parts of clinical specimens used for diagnostic purposes. No
separate consent is needed as long as the material is handled as
anonymous. The exempt from the informed consent is based on
the permit/licence granted by the National Supervisory Authority
for Welfare and Health of Finland (# 5280/04/046/06). For
indirect immunohistochemistry, 6-mm frozen tissue sections were
fixed in acetone at 220uC for 10 minutes and exposed first to
mAbs and then to FITC-coupled goat anti-mouse IgG (Jackson
Immunoresearch, West Grove, PA). After immunostaining, the
specimens were embedded in sodium veronal: glycerol buffer (1:1,
pH 8.4) and examined with a Leica Aristoplan microscope
equipped with appropriate filters (Leica, Bensheim, Germany).
Cell adhesion and migration assays
In cell adhesion and migration assays KG1C glioma, BE
melanoma and MDA-MB-231 carcinoma cells were used, as well
as function-blocking integrin (INT) mAbs P1B5 (INT a3)
(Millipore), GOH3 (INT a6) (R&D Systems, Abingdom, UK)
and 13 (INT b1) (BD Biosciences), together with mAbs to LMa5
chain.
The cell adhesion assay was performed in 96-well flat-bottomed
polystyrene plates (Maxisorp, Nunc) coated with either laminins
511 or 521 (20 mg/ml) for 1 hour at RT. Following three washes
with sterile PBS and blocking with 1% BSA for 1 hour, 100 ml of
cell suspension (106 cells/ml in RPMI-1640 medium with 0.1%
BSA) was added to the coated wells. Cell adhesion was allowed to
progress for 60 min at 37uC. Then, the wells were washed 5 times
with pre-warmed medium, and adhered cells were fixed with 4%
formaldehyde for 30 min and stained overnight with 0,5% toluidin
blue (Sigma-Aldrich). Finally, the plate was washed 5 times with
deionized water and 100 ml of 2% SDS was added to each well to
release the dye. A generic ELISA-reader (630 nm wavelength) was
used to measure the optical density. To test the effect of mAbs,
cells and coated wells were preincubated with integrin or laminin
antibodies (20 mg/ml), respectively, for 30 min before interacting.
Cell migration was performed in polycarbonate Transwell
culture inserts (Costar, Cambridge, MA, USA) with 8-mm pore size
membranes in 24-well plates. The membrane, which separates
upper and lower compartments, was coated on its bottom side
with laminins 511 or 521 (20 mg/ml) for one hour at 37uC and
then washed three times with sterile PBS. Thereafter, the inserts
were blocked with 0,1% BSA for 30 minutes and meticulously
washed 3–5 times with sterile PBS. Cells (16106 cells/ml) were
pre-treated for 15–20 minutes with integrin-blocking mAbs
(20 mg/ml) in RPMI 1640 and then 100 ml of this mixture was
added to each insert. Alternatively, 20 mg/ml of laminin mAb was
added to the cell suspension and to the lower chamber, which
contained 600 ml RMPI-1640. Cells were allowed to migrate at
37uC for 18 hours and the membranes then were fixed in 2%
glutaraldehyde and stained with haematoxylin. Following removal
of cells from the upper side of the membrane with cotton sticks,
cells attached to the lower side were counted using a microscope.
Mean cell number of four different representative fields (400x) was
calculated. Cell migration in the presence of mouse IgG was
defined as 100% control.
Binding of soluble a3b1 integrin to immobilized laminins
511 and 521 and effect of laminin mAbs
Direct receptor-ligand binding was measured by ELISA using
recombinant human a3b1 integrin (R&D Systems) and recombi-
nant human laminins 411, 511 and 521 (BioLamina). Briefly, 96-
well Maxisorp plates (Costar) were coated overnight at 4uC with
laminins at 5 mg/ml and, after blocking with 1% BSA, Mn++-
stimulated integrin (at 2,5 mg/ml) was added for 1 hour. Following
three washes, biotin-labeled goat anti-human integrin b1 antibody
(R&D Systems) was added at 1 mg/ml for 1 hour more. After three
additional washes, HRP-conjugated streptoavidin (Dako) was
added at 1:500 dilution and the enzyme activity was measured
using orthophenylenediamine. The plate was analyzed using a
generic ELISA reader (at 492 nm). Interfering mAbs at 20 mg/ml
were added to the immobilized laminins before incubation with
the integrin. Tris-buffered saline (TBS) was used throughout the
assay, including in the washing buffer (TBS with 0.1% BSA and
0.02%) and in the integrin-stimulating buffer (washing buffer with
2 mM MnCl2).
Statistical analysis
Results are presented as mean and standard deviation.
Significant differences were determined using paired Student’s t-
test. For all analyses, p,0.05 was considered statistically
significant: *, p,0.05; **, p,0.01; ***, p,0.001.
Results
Production and identification of novel mAbs to LMa5
chain
Considering the strong biological activity of laminin-511 and
the poor availability of reagents against the LMa5 chain, new
mAbs against this chain were generated using hybridoma
technology. Laminin-511 isolated from the supernatant of A549
lung adenocarcinoma cells was used as the immunogen. Among
the multiple laminin isoforms A549 cells selectively produce
laminin-511 [14] (M. Patarroyo, unpublished data). The cells were
Figure 3. mAb 8G9 to LMa5 chain strongly inhibits a3b1/a6b1 integrin-mediated cell adhesion to laminin-511 and, together with
LMa5 mAb 4C7, to laminin-521. A) KG1C glioma, B) BE melanoma and C) MDA-MB-231 breast carcinoma cells were used. Cells were allowed to
adhere to surfaces coated with rhLMs 511 or 521 (20 mg/ml) for 1 hour at 37uC. Statistical analyses (Student’s t-test) including mean and SD were
calculated, as well as level of significance comparing antibodies to mouse IgG (*, p,0.05; **, p,0.01; ***, p,0.001).
doi:10.1371/journal.pone.0053648.g003
A Function-Blocking mAb to Laminin alpha5 Chain
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found to express the LMa5 chain but not detectable amounts of
other laminin a chains, and Western blot analysis of immunopre-
cipitates from the conditioned medium with mAbs to LMa5 chain
under reducing conditions demonstrated presence of LMa5 (300/
350 kDa), LMb1 (230 kDa) and LMc1 (220 kDa), but not LMb2
(190 kDa), chains [14] (M. Patarroyo, unpublished data). The
isolated preparation used for immunization consisted of 300–350
and 220–230 kDa polypeptides with more than 95% purity as
demonstrated by silver staining of gels following electrophoresis
under reducing conditions. After a preliminary selection, five
clones were chosen for further study (4B5, 4F2, 5A6, 5G1, 8G9).
By comparison of the reactivity against recombinant human
laminin (rhLM) 511 and rhLM411 by ELISA, the novel mAbs
were found to selectively react with the former but not with the
latter (Fig. 1A), indicating specificity for the LMa5 chain, similarly
to the prototype mAb 4C7. Accordingly, these mAbs also reacted
with rhLM521. mAb 3H2 to LMa4 chain exclusively bound
rhLM411, whereas mAb DG10 to the LMb1 chain and mAb 22
to the LMc1 chain reacted with rhLM411 and rhLM511 and with
the three laminin isoforms, respectively, as expected. Similar level
of reactivity of mAb 22 to the LMc1 with immobilized rhLM411,
rhLM511 and rhLM521 indicated a comparable degree of
adsorption of the three laminin isoforms to the plastic surface
(Fig. 1A).
Ability of LMa5 chain-specific mAbs to react by Western
blotting under reducing conditions and to
immunoprecipitate
To further characterize the novel mAbs, their ability to
recognize the LMa5 chain in Western blotting under reducing
conditions was analyzed (Fig. 1B). Against rhLM511, mAb 4B5
strongly reacted with a polypeptide of 350 kDa. Less strong
reactivity was obtained with mAb 4F2 and a faint labeling was
detected with mAb 5G1. Other mAbs, including the prototype
mAb 4C7, were non-reactive.
In additional studies, the ability of the novel mAbs to
immunoprecipitate a5 laminins was tested in the culture
supernatant of A549 cells. The immunoprecipitated material was
visualized by Western blotting under reducing conditions by using
mAb 4B5 (Fig. 1C). Similarly to the prototype mAb 4C7, mAbs
4B5 and 8G9 were highly effective in immunoprecipitation,
followed by mAb 5G1. mAbs 4F2 and 5A6 were poor for
immunoprecipitation.
Immunohistological reactivity of newly developed mAbs
to LMa5 chain with kidney and skin sections when
compared to the prototype mAb 4C7
To confirm LMa5 chain specificity, reactivity of the novel
mAbs with frozen sections of human tissues was analyzed by
immunohistochemistry, and compared to that of mAb 4C7
(Fig. 2). The reactivity of all novel antibodies, but 4F2, was
indistinguishable from that of mAb 4C7 as they readily stained
glomerular and tubular BM in the kidney, and epidermal and
vascular BM in the skin (shown for mAb 8G9 against kidney
and skin in Fig. 2). Of interest, mAb 4F2 stained tubular,
epidermal and vascular BMs but not, or only minimally,
glomerular BMs indicating preferential reactivity with laminin-
511 when compared to laminin-521 (data not shown). This
pattern was originally observed by ELISA (Fig. 1A). The novel
mAbs were non-reactive with formalin fixed paraffin embed-
ded sections.
mAb 8G9 to LMa5 chain strongly inhibits a3b1 and a6b1
integrin-mediated cell adhesion and migration on
laminin-511 and, together with mAb 4C7, on laminin-521
In further studies, the function-blocking activity of the novel
mAbs was analyzed in cell adhesion to rhLM511 and rhLM521
(Fig. 3). These laminins were strongly adhesive for KG1C
glioma cells (OD values 1.48 and 1.39 for rhLM511 and
rhLM521, respectively), BE melanoma cells (OD values 1.65
and 1.56 for rhLM511 and rhLM521, respectively) and MDA-
MB-231 breast carcinoma cells (OD values 1.82 and 1.85 for
rhLM511 and rhLM521, respectively), when compared to
human serum albumin (HSA) (OD values 0.10, 0.10 and 0.09
for KG1C, BE and MDA-MB-231 cells, respectively) and the
cell adhesion was largely mediated by b1 integrins, preferen-
tially a3b1 and a6b1. Most notably, mAb 8G9 practically
abolished the adhesion of the three cell lines on rhLM511,
whereas mAb 5A6 and the prototype mAb 4C7 partially
reduced the adhesion of melanoma and breast cancer cells. In
contrast, mAb 8G9 was slightly inhibitory on rhLM521 when
tested alone, but its blocking effect was strongly synergized
with mAb 4C7 in the three cell lines.
In cell migration assays, rhLM511 and rhLM521 strongly
promoted migration of glioma cells (161 and 174 cells/field,
respectively), melanoma cells (88 and 203 cells/field, respectively)
and carcinoma cells (190 and 198 cells/field, respectively) when
compared to HSA (1 cell/field for all cell lines). As for cell
adhesion, cell migration was mediated via a3b1 and a6b1
integrins, and mAb 8G9 largely inhibited the migration of the
three cell types on rhLM511 (Fig. 4). Also similarly to cell
adhesion, mAb 8G9 alone slightly reduced cell migration on
rhLM521, but largely inhibited cell migration on this laminin
isoform when combined with mAb 4C7. mAb 8G9 did not inhibit
b1-integrin mediated cell migration on other extracellular matrix
proteins (data not shown).
mAb 8G9 to LMa5 chain interferes with the binding of
isolated a3b1 integrin to laminins 511 and 521
To investigate whether mAb 8G9 and other LMa5
antibodies could hinder the physical interaction of integrins
with laminins, the effect of the antibodies on the binding of
isolated recombinant a3b1 integrin to immobilized rhLM511
and rhLM521 was measured by ELISA (Fig. 5). The integrin
readily bound the two a5 laminins to a similar extent, but not
rhLM411 or albumin, and the binding was totally inhibited by
EDTA (Fig. 5A). Among the LMa5 antibodies, mAb 8G9
practically abolished the integrin interaction with rhLM511,
whereas mAb 5A6 exerted a modest, but statistically signifi-
cant, inhibitory effect (Fig. 5B). All other antibodies, including
mAb 4C7, were practically inactive. Similar results were
obtained with rhLM521 (Fig. 5C).
Figure 4. mAb 8G9 to LMa5 chain strongly inhibits a3b1/a6b1 integrin-mediated cell migration on laminin-511 and, together with
LMa5 mAb 4C7, on laminin-521. A) KG1C glioma, B) BE melanoma and C) MDA-MB-231 breast carcinoma cells were used. Cells were allowed to
migrate for 18 hours at 37uC through 8-mm pore-membranes coated with rhLMs 511 or 521 (20 mg/ml) on the lower surface. Statistical analyses
(Student’s t-test) including mean and SD were calculated, as well as level of significance comparing antibodies to mouse IgG (*, p,0.05; **, p,0.01;
***, p,0.001).
doi:10.1371/journal.pone.0053648.g004
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Figure 5. mAb 8G9 to LMa5 chain strongly inhibits binding of isolated a3b1 integrin to immobilized laminins 511 and 521. A) a3b1
integrin binds rhLMs 511 and 521, but not rhLM411. B) Effect of mAbs to LMa5 chain on the binding of a3b1 integrin to rhLM511. C) Effect of mAbs to
LMa5 chain on the binding of a3b1 integrin to rhLM521. Statistical analyses (Student’s t-test) including mean and SD were calculated, as well as level
A Function-Blocking mAb to Laminin alpha5 Chain
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mAb 8G9 defines an epitope located at or near to the
globular domain of laminin-511
The blocking activity of mAb 8G9 in the cell adhesion and
migration mediated by a3b1 and a6b1 integrins and in the
binding of isolated a3b1 integrin to a5 laminins suggested
localization of its target epitope at, or near, the globular domain
of the LMa5 chain; both integrins are known to recognize this
specific region [33]. To more closely determine the localization of
the epitope, competition of binding of biotinylated-mAb 8G9 to
immobilized rhLM511 with other mAbs to LMa5 chain was
analyzed by ELISA (Fig. 6). Non-labeled mAb 8G9 was highly
competitive, as expected, but all other antibodies, including mAb
4C7 which binds the LG1 module of the globular domain [41],
were practically inactive (Fig. 6A). In contrast, mAb 4E10, against
a LMb1 epitope located close to the globular domain of laminin-
511 [38], strongly interfered with the binding of biotinylated-mAb
8G9 (Fig. 6B).
Discussion
In the present study, we report development of five novel
mAbs to LMa5 chain. These antibodies were highly effective
for immunohistochemistry, Western blotting and immunopre-
cipitation. We also describe, for the first time, a mAb (8G9)
that efficiently inhibits integrin-dependent adhesion and
migration of a variety of cancer cells on laminin-511 and,
when combined with mAb 4C7, on laminin-521. The strong
adhesion- and migration-promoting activities of the a5
laminins, described for the first time for laminin-521 in the
present work, were found to be mediated by a3b1 and a6b1
integrins, in accordance with the known laminin isoform-
specific binding of integrins [31]. Furthermore, we report that
mAb 8G9 binds at, or near, the globular domain of the LMa5
chain and that the antibodies hinder the binding of a3b1
integrin to the a5 laminins.
The specificity of the mAbs was first established by ELISA
based on their reactivity with rhLM511, but not rhLM411, which
differ only in the a chain. Subsequently, the LMa5 specificity of
the mAbs was confirmed by Western blotting (4B5, 4F2, 5G1) and
immunoprecipitation (4B5, 5G1, 8G9). In contrast to the
prototype mAb 4C7, mAb 4B5 strongly reacted by Western
blotting and, similarly to 4C7, mAbs 4B5 and 8G9 were highly
effective for immunoprecipitation. The mAb 15H5, produced
against the recombinant domain IIIb of the short arm of the
human LMa5 chain, has also been reported to work for Western
blotting under reducing conditions [14]. Furthermore, all five
antibodies readily labeled frozen tissue sections. Of interest, the
immunohistochemical reactivity of mAb 4F2 differed to some
extent from that of the others. This antibody reacted with
epidermal, vascular and tubular BMs, as the other antibodies did,
but in contrast did not stain the glomerular BM. Because the latter
BM contains laminin-521 and the other BMs express laminin-511,
mAb 4F2 could be laminin-511-specific and differentiate between
the two a5 laminins. This inference was also supported by its
selective reactivity with rhLM511 when compared to rhLM521 by
ELISA. Theoretically, the LMb2 chain, but not LMb1, might
hinder binding of the antibody to the long arm of the LMa5 chain.
Lack of reactivity of the antibodies with formalin fixed paraffin
embedded sections indicated destruction of the corresponding
epitopes by the formalin fixation.
In contrast to laminin-511, the biological role of laminin-521 is
poorly known. This laminin isoform, which is found in the
glomerular BM in kidney, in the neuromuscular synaptic cleft in
skeletal muscle, in blood platelets and in other tissues [20,46] was,
at least, as active as laminin-511 in promoting cell adhesion and
migration via a3b1 and a6b1 integrins. In addition, it was bound
of significance of integrin binding to rhLMs 411, 511 and 521 when compared to HSA (A), and effect of antibodies when compared to mouse IgG on
integrin binding to rhLMs 511 (B) and 521 (C) (*, p,0.05; **, p,0.01; ***, p,0.001).
doi:10.1371/journal.pone.0053648.g005
Figure 6. mAb 4E10 to a LMb1 chain epitope near the globular domain of laminin-511 hinders the binding of mAb 8G9. A) mAb 4C7
and other LMa5 antibodies minimally affect the binding of mAb 8G9 to rhLM511. B) mAb 4E10 largely competes with the binding of mAb 8G9 to
rhLM511. Statistical analyses (Student’s t-test) including mean and SD were calculated, as well as level of significance of the effect of the mAbs on the
binding of biotinylated-8G9 to rhLM511 when compared to mouse IgG. Competing antibodies were used at 50x higher concentration than
biotinylated-8G9 (*, p,0.05; **, p,0.01; ***, p,0.001).
doi:10.1371/journal.pone.0053648.g006
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to a slightly higher degree by a3b1 integrin than laminin-511.
These results agree with a recent report from Taniguchi et al. [47]
describing more avid binding of b2 laminins to integrins such as
a3b1 when compared to b1 laminins.
Among our findings, the strong inhibitory effect of mAb 8G9 on
cell adhesion and migration was remarkable. The mAb 4C7 has
been previously reported to be a function-blocking mAb
[34,38,40,41], but our data demonstrated the superiority of mAb
8G9. Considering that the cell adhesion and migration on
laminins 511 and 521 was mediated by a3b1 and a6b1 integrins
and that these integrins recognize the globular domain of the
LMa5 chain [33], it was plausible to assume that mAb 8G9
interacted with, or near, the globular domain and recognized a site
at, or near, the binding sites of these two integrins. The former was
proven by the ability of mAb 4E10, which binds to a LMb1
epitope close to the globular domain [38], to compete out the
binding of mAb 8G9. Moreover, interference of soluble integrin
binding to the a5 laminins was demonstrated for a3b1. The latter
studies with soluble a3b1 integrin also confirmed the isoform-
specific interaction with laminins, as this integrin bound laminins
511 and 521, but not laminin-411 [31]. Whether mAb 8G9 and
the other novel mAbs hinder the binding of a6b1, a6b4, a7b1 and
other integrins to laminins 511 and 521 is currently under
investigation.
The more effective inhibition of cell adhesion and migration on
laminin-511, when compared to laminin521, by mAb 8G9 may be
explained by its preferential binding to the former laminin isoform
as detected by ELISA. This preferential behaviour may be due to
modulation of the antibody binding by the C-terminal region of
the laminin b1 and b2 chains, as demonstrated for integrin
binding [47]. In contrast to mAb 8G9, which abolished the
binding of soluble a3b1 integrin to a5 laminins, mAb 4C7 was
practically inactive in this assay. However, the latter mAb is known
to bind the LG1 module of the globular domain and to inhibit
binding of a6b1 integrin to laminin-511 [41]. Together, these
findings indicate that the binding site(s) of these two integrins,
known to be located at LG1-3 modules of the LMa5 chain
globular domain [33], are close to one another but clearly distinct.
mAbs 8G9 and 4C7 appear to inhibit preferentially binding of
a3b1 and a6b1 integrins, respectively, and the two antibodies
exert a complementary inhibitory effect on cells that express both
integrins.
The strong inhibitory effect of mAb 8G9 on adhesion and
migration on laminin-511 and, together with mAb 4C7, on
laminin-521 in cells derived from different tumor types, namely
glioma, melanoma and breast carcinoma, was striking considering
that their integrin repertoire was not identical [22,24,48].
However, all cell lines expressed and used a3b1 and a6b1
integrins [22,24,48], suggesting a rather common mechanism in
tumor cell adhesion and migration and, probably, invasiveness.
Altogether, the present results indicate that the five novel mAbs
recognize five different epitopes on the LMa5 chain, distinct from
the one defined by mAb 4C7. These reagents may constitute
valuable tools for a better understanding of the role of a5 laminins
in cell and tumor biology. mAb 8G9 may be the LMa5 antibody
homologue of function-blocking mAbs BM165 and CM6 against
the globular domain of the human and rat LMa3 chains,
respectively [49,50]. Recently, mAbs to the globular domain of
the human LMa3 chain were shown to inhibit growth of human
epithelial tumors grafted in mice [51,52]. Likewise, antagonists of
a5 laminins may inhibit tumor invasion and metastasis and have
therapeutic potential in malignant diseases. Since immune cells
similarly interact with a5 laminins in adhesion and migration,
these inhibitory agents may also have a beneficial effect in
inflammatory disorders [23,32].
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